insights_auto
Hvorfor er 000739 faldet med 2,89%?
Dyk dybere nedchevron_right
000739:SHE
Apeloa Pharmaceutical Co Ltd
23,88Â CNÂ¥
arrow_downward
-2,89%(-0,71) 1D
15. okt., 14.12.48 GMT+8 · CNY
search
Alle symboler
| Symbol | Pris | Ændring | Ændring i % |
|---|
insights_autoGenererer vigtig indsigt for 000739...
Ã…bn
24,10Â CNÂ¥
Høj
24,94Â CNÂ¥
Lav
23,60Â CNÂ¥
Markedsværdi
28,68Â mia.
Gns. vol.
16,22Â mio.
Volumen
11,94Â mio.
Udbytte
1,58Â %
Kvartalsvis udbytte
0,09Â CNÂ¥
Ex-dato
8. okt. 2026
P/E-forhold
32,41
Højeste i 52 uger
28,50Â CNÂ¥
Laveste i 52 uger
14,89Â CNÂ¥
Indtægt pr. aktie
0,74Â CNÂ¥
Aktier i omløb
1,16Â mia.
Antal ansatte
7Â t
Ã…bn
24,10Â CNÂ¥
Høj
24,94Â CNÂ¥
Lav
23,60Â CNÂ¥
Markedsværdi
28,68Â mia.
Gns. vol.
16,22Â mio.
Volumen
11,94Â mio.
Udbytte
1,58Â %
Kvartalsvis udbytte
0,09Â CNÂ¥
Ex-dato
8. okt. 2026
P/E-forhold
32,41
Højeste i 52 uger
28,50Â CNÂ¥
Laveste i 52 uger
14,89Â CNÂ¥
Indtægt pr. aktie
0,74Â CNÂ¥
Aktier i omløb
1,16Â mia.
Antal ansatte
7Â t
Nyhedshistorier
Fra webkilder og nyhedspartnere
Traders Union
·
for 18 timer siden
Mike McGlone: Kobberfutures og S&P 500 når rekordhøj korrelation
MarketBeat
·
for 31 minutter siden
Plug Power (NASDAQ:PLUG) Hits New 1-Year Low Following Analyst Downgrade
Yahoo Finance
·
for 2 timer siden
SKHY Tracks Worst Month Since Nasdaq Debut: SK Hynix Reportedly Wants To Ship More Chip Tools To China Before Building In US
www.marketscreener.com
·
for 1 time siden
IPAS Indexo : INDEXO submits draft Company Description to Nasdaq Stockholm for preliminary review
Profil
Apeloa Pharmaceutical Co., Ltd., known as Apeloa, is a Chinese pharmaceutical manufacturer under Hengdian Group. The company is headquartered in Hengdian, Dongyang, Zhejiang, China. It was founded in 1989 and has been listed on the Shenzhen Stock Exchange since 9 May 1997. Apeloa provides contract development and manufacturing services and manufactures APIs and finished dosage forms; products span cardiovascular, anti-infective, psychiatric and oncology areas.
Apeloa has 7400 employees, 8 manufacturing sites and 3 R&D centers in Boston, Shanghai and Hengdian, covering flow chemistry, synthetic biology and biocatalysis, and peptide development. It has invested over USD20 million in flow chemistry over the past ten years in an effort to advance sustainable pharmaceutical manufacturing. In Boston, its 17,000-square-foot facility does R&D related to chemistry needs in drug development, including preclinical chemistry, scale-up production and new drug development.
Apeloa Pharmaceutical has successfully passed 20 U.S. FDA inspections since 2006. Wikipedia
Om Apeloa Pharmaceutical Co Ltd